Figure 1.
NRG-CC011 SCHEMA



*All potential participants will be registered in Step 0.
**If a participant meets all eligibility requirements, provides written informed consent, and completes the baseline assessment (both surveys via VTOC tool and neuropsychological assessment), the participant will be randomized in Step 1.
**Randomization is 1:1
Registration (Step 0) and Randomization (Step 1) are a collaboration of NRG Oncology sites, NRG SDMC, and Ohio State University (shading represents the steps where sites are involved). The baseline assessment is a function of the NRG Oncology SDMC and Ohio State University only.

3.2 Eligibility Criteria

A participant cannot be considered eligible for this study unless ALL of the following conditions are met. (Specifically, all criteria must be met at Step 0-Registration)

3.2.1 The participant must provide study-specific informed consent prior to any study specific procedures and authorization permitting release of personal health information.

3.2.2 The participant must be ≥ 18 years of age.

3.2.3 The participant must have a first time diagnosis of non-metastatic breast cancer which is Stage I-III.

3.2.4 The participant must have a score of < 12 on the PROMIS Adult v2.0 - Cognitive Function 4a.

3.2.5 Participants with ≥ 6 months to 5 years post-treatment (completion of initial surgery +/- adjuvant chemotherapy/radiation therapy) except may still be taking endocrine therapy or HER2-directed adjuvant therapy.

3.2.6 The participant must be able to understand, speak, read, and write in English or Spanish.

3.3 Ineligibility Criteria

Participants with any of the following conditions are NOT eligible for this study.

3.3.1 Scoring ≤ 3 on the 6-item cognitive screen.

3.3.2 Patient Health Questionnaire-2 item (PHQ-2) score of ≥ 3.

3.3.3 Definitive clinical or radiologic evidence of metastatic disease.

3.3.4 Prior history of past or current other cancer, except for non-melanoma skin cancer or in situ cervical cancer within the past 5 years.

3.3.5 Previous exposure to chemotherapy treatment for another cancer or due to other medical condition (e.g. methotrexate exposure for treatment of rheumatoid arthritis).

3.3.6 Previous CNS radiation, intrathecal therapy or CNS-involved surgery.

3.3.7 Participants with history of stroke, traumatic brain injury, brain surgery, Alzheimer's disease or other dementia.

3.3.8 Participants with active substance abuse and/or in treatment for substance abuse, or history of bipolar disorder, psychosis, schizophrenia, ADHD, or learning disability.

3.3.9 Participants who are enrolled in other therapeutic trials and/or quality of life trials.